Read More Pharma Industry News Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field. byVenkateshJanuary 22, 2026